quaratusugene ozeplasmid

BIOLOGICAL3 trials

Sponsors

Genprex, Inc.

Conditions

Carcinoma, Non-Small Cell LungNon Small Cell Lung CancerSmall Cell Lung Cancer Extensive Stage

Phase 1

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

RecruitingNCT04486833

Genprex, Inc.Carcinoma, Non-Small Cell Lung

Start: 2021-09-03End: 2029-03-01Target: 158Updated: 2026-01-21

Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer

TerminatedNCT05062980

Genprex, Inc.Non Small Cell Lung Cancer

Start: 2022-03-30End: 2025-02-03Updated: 2025-02-20

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

RecruitingNCT05703971

Genprex, Inc.Small Cell Lung Cancer Extensive Stage

Start: 2024-05-09End: 2027-08-31Target: 62Updated: 2025-10-16

Related Papers

A phase 1/2 clinical trial of quaratusugene ozeplasmid gene therapy and atezolizumab maintenance therapy in patients with extensive stage small cell lung cancer (ES-SCLC).

Journal of Clinical Oncology2025-05-28

ACCLAIM-1 dose escalation: Determination of quaratusugene ozeplasmid and osimertinib recommended phase 2 dose (RP2D).

Journal of Clinical Oncology2023-06-01